Document Detail


Is technological change in medicine always worth it? The case of acute myocardial infarction.
MedLine Citation:
PMID:  16464904     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We examine Medicare costs and survival gains for acute myocardial infarction (AMI) during 1986-2002. As David Cutler and Mark McClellan did in earlier work, we find that overall gains in post-AMI survival more than justified the increases in costs during this period. Since 1996, however, survival gains have stagnated, while spending has continued to increase. We also consider changes in spending and outcomes at the regional level. Regions experiencing the largest spending gains were not those realizing the greatest improvements in survival. Factors yielding the greatest benefits to health were not the factors that drove up costs, and vice versa.
Authors:
Jonathan S Skinner; Douglas O Staiger; Elliott S Fisher
Related Documents :
20832064 - Association of cd40 ligand levels in the culprit coronary arteries with subsequent prog...
19938054 - Oral l-arginine supplementation in acute myocardial infarction therapy: a meta-analysis...
8556774 - Acute myocardial infarction in zimbabwe: the changing scene of coronary artery disease.
9084994 - Validity of diagnoses of major coronary events in national registers of hospital diagno...
6144264 - Role of beta-adrenoreceptor antagonism in the prevention of reperfusion ventricular arr...
16375634 - Chagas cardiomyopathy and ischemic stroke.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2006-02-07
Journal Detail:
Title:  Health affairs (Project Hope)     Volume:  25     ISSN:  1544-5208     ISO Abbreviation:  Health Aff (Millwood)     Publication Date:    2006 Mar-Apr
Date Detail:
Created Date:  2006-03-08     Completed Date:  2006-10-10     Revised Date:  2013-04-24    
Medline Journal Info:
Nlm Unique ID:  8303128     Medline TA:  Health Aff (Millwood)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  w34-47     Citation Subset:  IM    
Affiliation:
Dartmouth Medical College.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adrenergic beta-Antagonists / therapeutic use
Aged
Biomedical Technology / economics*
Cardiac Catheterization
Cost-Benefit Analysis
Female
Humans
Male
Medicare / economics*
Myocardial Infarction / economics*,  mortality*,  therapy
Proportional Hazards Models
Survival Analysis
Technology Assessment, Biomedical / economics*
Treatment Outcome
United States
Grant Support
ID/Acronym/Agency:
P01 AG019783/AG/NIA NIH HHS; P01 AG019783-06/AG/NIA NIH HHS; P01-AG19783/AG/NIA NIH HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists
Comments/Corrections
Comment In:
Health Aff (Millwood). 2006 Mar-Apr;25(2):w48-50   [PMID:  16464902 ]
Health Aff (Millwood). 2006 Mar-Apr;25(2):w51-3   [PMID:  16464903 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  To use technology better.
Next Document:  Whole genome microarray analysis of growth hormone-induced gene expression in bone: T-box3, a novel ...